



DECEMBER 11-12, 2025  
۲۱ و ۲۰ آذر ماه ۱۴۰۴



دومین کنگره  
پلازما پزشکی ایران

The 2<sup>nd</sup> Congress on Plasma Medicine

دبیرخانه دائمی کنگره  
پلازما پزشکی ایران  
www.plasmamedsym.ir



# Cold Atmospheric Plasma as a Promising Strategy Against Emerging Antifungal Resistance in Dermatophytosis

Tahereh Shokohi<sup>1\*</sup>, Maryam Salimi<sup>1</sup>, Zohreh Hajheidari<sup>2</sup>,  
Anahita Mohsenpour<sup>1</sup>, Seyedehniaz Hadavi<sup>3</sup>, Farshad Sohbatzadeh<sup>3</sup>

<sup>1</sup>Invasive Fungi Research Centre (IFRC), Communicable diseases Institutes/Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

<sup>2</sup>Department of Dermatology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

<sup>3</sup>Department of Nuclear and Molecular Physics, Faculty of Science, University of Mazandaran, Babolsar, Iran

## OPEN ACCESS

## ABSTRACT

### Citation:

Shokohi T. Cold Atmospheric Plasma as a Promising Strategy Against Emerging Antifungal Resistance in Dermatophytosis. *Iran Biomed J. Supplementary* (2-2026): 55.

Dermatophytosis (tinea) affects approximately 20–25% of the global population. The majority of skin and nail infections are caused by the *Trichophyton mentagrophytes* complex and *T. rubrum*. However, a novel species, *T. indotineae*, is rapidly emerging as a significant concern, replacing *T. rubrum*. This species poses a serious threat due to frequent resistance to terbinafine resistance, which is caused by mutations in the squalene epoxidase gene. This growing resistance, especially to terbinafine, represents a global health concern. In Iran, for instance, *T. indotineae* is increasingly prevalent, with approximately 15% of isolates resistant to terbinafine. While alternative antifungals exist, they often come with adverse effects, and resistance to these medications is also rising, underscoring the need for safer, more effective treatments. Preclinical studies have shown that cold atmospheric plasma (CAP) can inhibit the germination of dermatophyte conidia, hinder hyphal growth, and reduce the potential for infection. Early clinical reports suggest that CAP could be a promising and safe adjunct therapy for chronic dermatophytosis, particularly in antifungal-refractory cases. To advance this evidence, our team has designed a triple-blinded randomized clinical trial to evaluate CAP's efficacy in treating refractory dermatophytosis. We hope this study will address significant challenges and pave the way for the future clinical adoption of CAP.



This article is licensed under a Creative Commons Attribution-NonDerivatives 4.0 International License.

**Keywords:** Antifungal resistance, Cold atmospheric plasma, Dermatophytosis, *T. indotineae*

### Corresponding Author: Tahereh Shokohi

Invasive Fungi Research Centre (IFRC), Communicable diseases Institutes/Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran; E-mail: shokohi.tahereh@gmail.com



Iranian Biomedical Journal Supplementary (February 2026): 55